Science 37 Uses the Direct-to-Patient Site to Support Clinical Trial in Rare Neurodegenerative Disease

An industry leading pharmaceutical company implemented the Science 37’s Direct-to-Patient Site to reduce patient patient burden and accelerate trial timelines.

Learn how the Direct-to-Patient Site expanded reach beyond site confines - bringing both neurological assessments and pharmacokinetic blood draws from the comfort of home.